Literature DB >> 12562873

Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis.

Gustav Schonfeld1, Bruce W Patterson, Dmitriy A Yablonskiy, Tariq S K Tanoli, Maurizio Averna, Nizar Elias, Pin Yue, Joseph Ackerman.   

Abstract

Familial hypobetalipoproteinemia (FHBL) subjects may develop fatty liver. Liver fat was assessed in 21 FHBL with six different apolipoprotein B (apoB) truncations (apoB-4 to apoB-89) and 14 controls by magnetic resonance spectroscopy (MRS). Liver fat percentages were 16.7 +/- 11.5 and 3.3 +/- 2.9 (mean +/- SD) (P = 0.001). Liver fat percentage was positively correlated with body mass index, waist circumference, and areas under the insulin curves of 2 h glucose tolerance tests, suggesting that obesity may affect the severity of liver fat accumulation in both groups. Despite 5-fold differences in liver fat percentage, mean values for obesity and insulin indexes were similar. Thus, for similar degrees of obesity, FHBL subjects have more hepatic fat. VLDL-triglyceride (TG)-fatty acids arise from plasma and nonplasma sources (liver and splanchnic tissues). To assess the relative contributions of each, [2H2]palmitate was infused over 12 h in 13 FHBL subjects and 11 controls. Isotopic enrichment of plasma free palmitate and VLDL-TG-palmitate was determined by mass spectrometry. Non-plasma sources contributed 51 +/- 15% in FHBL and 37 +/- 13% in controls (P = 0.02). Correlations of liver fat percentage and percent VLDL-TG-palmitate from liver were r = 0.89 (P = 0.0001) for FHBL subjects and r = 0.69 (P = 0.01) for controls. Thus, apoB truncation-producing mutations result in fatty liver and in altered assembly of VLDL-TG.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12562873     DOI: 10.1194/jlr.M200342-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  42 in total

1.  Lipoproteins: When size really matters.

Authors:  J Bruce German; Jennifer T Smilowitz; Angela M Zivkovic
Journal:  Curr Opin Colloid Interface Sci       Date:  2006-06       Impact factor: 6.448

2.  A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

Authors:  Ingrid K Kotowski; Alexander Pertsemlidis; Amy Luke; Richard S Cooper; Gloria L Vega; Jonathan C Cohen; Helen H Hobbs
Journal:  Am J Hum Genet       Date:  2006-01-20       Impact factor: 11.025

3.  Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, two-point dixon and three-point IDEAL.

Authors:  Hyeonjin Kim; Sara E Taksali; Sylvie Dufour; Douglas Befroy; T Robin Goodman; Kitt Falk Petersen; Gerald I Shulman; Sonia Caprio; R Todd Constable
Journal:  Magn Reson Med       Date:  2008-03       Impact factor: 4.668

4.  Clinical utility gene card for: Familial Hypobetalipoproteinaemia (APOB).

Authors:  John R Burnett; Damon A Bell; Amanda J Hooper; Robert A Hegele
Journal:  Eur J Hum Genet       Date:  2012-05-16       Impact factor: 4.246

5.  A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia.

Authors:  Angelo B Cefalù; James P Pirruccello; Davide Noto; Stacey Gabriel; Vincenza Valenti; Namrata Gupta; Rossella Spina; Patrizia Tarugi; Sekar Kathiresan; Maurizio R Averna
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-30       Impact factor: 8.311

Review 6.  Hypobetalipoproteinemia and abetalipoproteinemia.

Authors:  Francine K Welty
Journal:  Curr Opin Lipidol       Date:  2014-06       Impact factor: 4.776

7.  Clinical utility gene card for: Familial hypobetalipoproteinaemia (APOB)--Update 2014.

Authors:  John R Burnett; Damon A Bell; Amanda J Hooper; Robert A Hegele
Journal:  Eur J Hum Genet       Date:  2014-10-22       Impact factor: 4.246

Review 8.  Molecular biology of PCSK9: its role in LDL metabolism.

Authors:  Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  Trends Biochem Sci       Date:  2007-01-09       Impact factor: 13.807

9.  Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.

Authors:  Maartje E Visser; Fatima Akdim; Diane L Tribble; Aart J Nederveen; T Jesse Kwoh; John J P Kastelein; Mieke D Trip; Erik S G Stroes
Journal:  J Lipid Res       Date:  2009-12-14       Impact factor: 5.922

10.  Common and rare gene variants affecting plasma LDL cholesterol.

Authors:  John R Burnett; Amanda J Hooper
Journal:  Clin Biochem Rev       Date:  2008-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.